FDA grants full approval for antiviral pill to treat mild-to-moderate COVID-19 in adults
The U.S. Food and Drug Administration (FDA) on Thursday approved Pfizer’s Paxlovid, an oral antiviral drug for the treatment of mild-to-moderate COVID-19 in adults. Read More
Medical records link vaccination against COVID-19 to reduced risk of non-respiratory symptoms
Fully vaccinated individuals had a lower risk of dying or developing some non-respiratory symptoms than people without protection against COVID-19 during the Delta and Omicron waves, a retrospective review of medical records has found. Read More
A closer look at long COVID symptoms
Patients with persistent neurological symptoms after SARS-CoV-2 infections were intensively studied and found to have autonomic dysfunction and differences in their immune cell profiles. The findings, published last Friday in Neurology: Neuroimmunology & Neuroinflammation, may help explain lingering long-COVID neurological symptoms, and lead to better diagnoses and treatments. Read More
Targeting viral RNA to treat infection
Despite the rapid development of COVID-19 vaccines, the rise of variants forces scientists to frequently modify treatments. A new study published Wednesday in ACS Central Science describes a treatment that directly targets and degrades the viral ribonucleic acid (RNA) genome, reducing SARS-CoV-2 infection in mice. Read More
Infectious SARS-CoV-2 found in hospital air
Quebec researchers isolated infectious SARS-CoV-2 virus particles from air samples that were originally collected from COVID-19 patients’ hospital rooms, then kept frozen for more than a year. Read More
Plasmid DNA vaccine protects mice from COVID-19 by triggering T-cell response
A plasmid DNA vaccine designed to trigger a T-cell response has protected most mice from a lethal dose of SARS-CoV-2, delivering preliminary evidence that the candidate may provide broader, more durable responses than existing COVID-19 shots. Read More
English study finds demographic differences in COVID-19 rates between pandemic waves
An observational study in England found major ethnic, religious, and social differences in the risk of testing positive for SARS-CoV-2 between the second and third waves of the pandemic. Read More
Monoclonal antibodies reduced COVID-19 hospitalization, death risk by a third: Study
During the COVID-19 pandemic, healthcare providers nationwide administered an evolving array of monoclonal antibody treatments, previously untested on such a large scale. A study, published Monday in the Annals of Internal Medicine, showed that this effort saved lives. Read More
Pandemic played out in vastly different ways across the U.S.: Study
A comprehensive state-by-state analysis of COVID-19 impacts across the U.S. revealed the underlying forces driving wide variations in health, education, and economic performance. Read More
Rapid nirmatrelvir treatment may reduce long COVID risk
A study of people with SARS-CoV-2 infection who had at least one risk factor for progression to severe disease found that treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result was associated with reduced risk of post−COVID-19 condition, known as long COVID. The findings, published Thursday in JAMA Internal Medicine, held true across the risk spectrum in this cohort, regardless of vaccination status and history of prior infection. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter